Skip to main content

Table 1 Relationship between STAT3 promoter methylation, patient clinical characteristics and PA invasiveness

From: Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma

 

STAT3 gene methylation

Number of patients

M (%)

U (%)

p-value

Cases

102

11(10.78)

91(89.22)

 

Age (years)

  ≤ 60

40

4(10.00)

36(90.00)

0.837

  > 60

62

7(11.29)

55(88.71)

Gender

 Female

58

6(10.34)

52(89.66)

0.870

 Male

44

5(11.36)

39(88.64)

PA function

 Secreting

54

6(11.11)

48(88.89)

0.910

 Non-secreting

48

5(10.42)

43(89.58)

Relapse

 Appear

8

1(12.50)

7(87.50)

0.871

 None

94

10(10.64)

84(89.36)

Prolactinoma

 Appear

36

4(11.11)

32(88.89)

1.000

 None

18

2(11.11)

16(88.89)

Acromegaly

 Appear

9

1(11.11)

8(88.89)

1.000

 None

45

5(11.11)

40(88.89)

Cushing syndrome

 Appear

1

0(0.00)

1(100.00)

0.721

 None

53

6(11.32)

47(88.68)

Hormones

 PRL

36

4(11.11)

32(88.89)

 

 IGF-1

2

0(0.00)

2(100.00)

 GH

4

2 (50.00)

2(50.00)

 ACTH

1

0(0.00)

1(100.00)

 Multiple

11

0(0.00)

11(100.00)

Invasiveness

 Invasive

58

7(12.07)

51(87.93)

0.428

 Non-invasive

30

2(6.67)

28(93.33)

  1. M methylated, U non-methylated, PRL prolactin, IGF-1 insulin-like grow factor 1, GH growth hormone, ACTH – adrenocorticotropic hormone, multiple – PAs secreting more than one hormone